miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer

Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of microRNAs in the trastuzumab response, we performed a microRNA array in paren...

Descripción completa

Detalles Bibliográficos
Autores: Cabello, Paula, Torres-Ruiz, Sandra, Adam-Artigues, Anna, Forés-Martos, Jaume, Martínez, María Teresa, Hernando, Cristina, Zazo, Sandra, Madoz-Gúrpide, Juan, Rovira, Ana, Burgués, Octavio, Rojo, Federico, Albanell Mestres, Joan, Lluch, Ana, Bermejo, Begoña, Cejalvo, Juan Miguel, Eroles, Pilar
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/59268
Acceso en línea:http://hdl.handle.net/10230/59268
http://dx.doi.org/10.3390/cancers15072138
Access Level:acceso abierto
Palabra clave:HER2+ breast cancer
Exosomes
miR-146a-5p
Resistance
Trastuzumab
Descripción
Sumario:Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of microRNAs in the trastuzumab response, we performed a microRNA array in parental and acquired trastuzumab-resistant HER2-positive breast cancer cell lines. Our results identified miR-146a-5p as the main dysregulated microRNA. Interestingly, high miR-146a-5p expression in primary tumor tissue significantly correlated with shorter disease-free survival in HER2-positive breast cancer patients. The gain- and loss-of-function of miR-146a-5p modulated the response to trastuzumab. Furthermore, the overexpression of miR-146a-5p increased migration and angiogenesis, and promoted cell cycle progression by reducing CDKN1A expression. Exosomes from trastuzumab-resistant cells showed a high level of miR-146a-5p expression compared with the parental cells. In addition, the co-culture with resistant cells' exosomes was able to decrease in sensitivity and increase the migration capacities in trastuzumab-sensitive cells, as well as angiogenesis in HUVEC-2 cells. Collectively, these data support the role of miR-146a-5p in resistance to trastuzumab, and demonstrate that it can be transferred by exosomes conferring resistance properties to other cells.